Warren, New Jersey, September 12, 2025
News Summary
Tevogen Bio Holdings Inc. has signed a lease to double its headquarters in Warren, New Jersey, reaching approximately 13,000 square feet. This expansion aims to centralize cross-functional teams and support AI initiatives, including the Tevogen.AI and Generics & Biosimilars initiatives. The new facility will enhance collaboration among leadership, regulatory, and research teams, as well as accommodate a growing team of data scientists and engineers. The company plans a ribbon-cutting ceremony to celebrate this significant investment in its operational capabilities and future growth.
Warren, New Jersey — Tevogen Bio Expands Headquarters to Support Growth and AI Initiatives
Tevogen Bio Holdings Inc. has signed a lease to expand its corporate headquarters in Warren, New Jersey, effectively doubling its footprint to approximately 13,000 square feet. The immediate purpose of the expansion is to centralize cross-functional teams and to provide dedicated facilities for Tevogen.AI and the company’s Generics & Biosimilars initiative, supporting operational efficiency and collaboration as the company scales.
Key details
The expanded space will bring together executive leadership, regulatory affairs, corporate strategy, and research and development teams that were previously dispersed, including personnel based in Philadelphia. The new facility will also house Tevogen.AI’s growing team of data scientists and engineers, enabling in-house development and deployment of the company’s proprietary algorithms, AdapTcell and PredicTcell, which were developed in collaboration with Microsoft and Databricks.
Space, ownership and location rationale
The leased space previously was occupied by CAPTRUST, a national investment advisory firm, and is owned by Mitsui Sumitomo Insurance Company of America. Tevogen has maintained operations in Warren for more than five years and selected the town for its proximity to established life science infrastructure, access to talent, and a business-oriented environment. The company has indicated the expanded headquarters could also accommodate potential new business units as it continues to diversify.
Operational impact and staffing
As of June 2025, Tevogen reported 19 full-time employees. The new headquarters is intended to improve day-to-day coordination across teams, enable closer integration of AI and lab-based work, and support the scaling of Tevogen’s clinical and commercial initiatives. Dedicated facilities for Tevogen.AI are expected to provide the tools and workspace needed for ongoing algorithm development and for application of AI tools to precision immunotherapy.
Financial and market context
In early trading following the expansion announcement, Tevogen’s shares declined by 3.9% to $1.38. Year-to-date, the stock had risen approximately 37%. The company’s market capitalization is estimated at about $259.3 million. Company statements accompanying the lease announcement positioned the expansion as an investment in operational capability and future growth rather than a direct fundraising or M&A activity.
Planned events and external engagement
A ribbon-cutting ceremony for the expanded headquarters will be planned with local officials and community partners. Separately, Tevogen’s Chief Information Officer is scheduled to participate in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025, at the Sheraton Boston Hotel, where he will address the application of AI technologies in precision immunotherapy alongside venture capital and industry innovators.
Background and strategic significance
The expansion aligns with a broader strategy to combine life science research, regulatory operations, and AI-driven analytics under a single corporate roof. Bringing Tevogen.AI and the Generics & Biosimilars initiative into the headquarters is intended to accelerate algorithm development, streamline regulatory communications, and shorten feedback loops between computational teams and laboratory or clinical functions. The company positions these moves as part of longer-term efforts to advance healthcare offerings while maintaining flexibility to add new business units as opportunities arise.
FAQ
What is the size of the new Tevogen headquarters?
The expanded headquarters will be approximately 13,000 square feet, roughly double the company’s previous Warren footprint.
Which teams will be centralized at the Warren location?
Executive leadership, regulatory affairs, corporate strategy, research and development, Tevogen.AI, and the Generics & Biosimilars initiative will be centralized at the expanded headquarters.
What is Tevogen.AI and what will the new space support?
Tevogen.AI is the company’s in-house AI organization focused on data science and engineering for precision immunotherapy. The new space will include dedicated facilities for data scientists and engineers to develop and maintain proprietary algorithms, including AdapTcell and PredicTcell.
Who previously occupied the leased space and who owns it?
The space was formerly occupied by CAPTRUST and is owned by Mitsui Sumitomo Insurance Company of America.
How many employees does Tevogen currently have?
As of June 2025, Tevogen reported having 19 full-time employees.
Will there be a public event to mark the expansion?
A ribbon-cutting ceremony is planned with local officials and community partners; timing and details will be announced by the company.
How did the market react to the announcement?
Tevogen’s shares fell 3.9% to $1.38 in early trading after the announcement, while the stock has increased about 37% year-to-date. The company’s market capitalization is estimated at $259.3 million.
Quick Reference Table
| Item | Detail |
|---|---|
| Location | Warren, New Jersey |
| New Headquarters Size | Approximately 13,000 sq ft |
| Primary Initiatives Hosted | Tevogen.AI; Generics & Biosimilars |
| Previously Occupied By | CAPTRUST |
| Property Owner | Mitsui Sumitomo Insurance Company of America |
| Full-Time Employees (June 2025) | 19 |
| Market Capitalization | Approximately $259.3 million |
| Stock Movement After Announcement | Down 3.9% to $1.38; up ~37% YTD |
| Planned Public Event | Ribbon-cutting ceremony with local officials (date TBA) |
| Upcoming External Presentation | Databricks DATA + AI World Tour Startup Forum, Oct 8, 2025 (Sheraton Boston Hotel) |
Deeper Dive: News & Info About This Topic
HERE Resources
Boston’s Office Market Shows Signs of Stabilization
Tevogen Bio’s Mittul Mehta to Speak at Startup Forum
Additional Resources
- NJB Magazine
- ROI-NJ
- Quiver Quant
- GlobeNewswire
- NJBIZ
- Wikipedia: Artificial Intelligence
- Google Search: Tevogen Bio
- Google Scholar: Tevogen Bio
- Encyclopedia Britannica: Tevogen Bio
- Google News: Tevogen Bio
Author: STAFF HERE BOSTON WRITER
BOSTON STAFF WRITER The BOSTON STAFF WRITER represents the experienced team at HEREBoston.com, your go-to source for actionable local news and information in Boston, Suffolk County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Boston Marathon, Head of the Charles Regatta, and Boston Harborfest. Our coverage extends to key organizations like the Greater Boston Chamber of Commerce and Associated Industries of Massachusetts, plus leading businesses in finance, biotech, and insurance that power the local economy such as Fidelity Investments, Biogen, and Liberty Mutual Insurance. As part of the broader HERE network, we provide comprehensive, credible insights into Massachusetts's dynamic landscape.
